Jenn Buechel
President presso Delfi Diagnostics, Inc.
Profilo
Jenn Buechel is currently the Director at MOBILion Systems, Inc., a Member at Aspen Global Leadership Network, and the President & Chief Operating Officer at Delfi Diagnostics, Inc. She has a graduate degree and an MBA from Stanford University, as well as an undergraduate degree from Queen's University.
Posizioni attive di Jenn Buechel
| Società | Posizione | Inizio |
|---|---|---|
Delfi Diagnostics, Inc.
 Delfi Diagnostics, Inc. Medical/Nursing ServicesHealth Services Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD. | President | 23/02/2023 |
MOBILion Systems, Inc.
 MOBILion Systems, Inc. Packaged SoftwareTechnology Services MOBILion Systems, Inc. offers paradigm-shifting platform technology. It will Develop a cost effective analytical system with a small footprint, high throughput, ultra-high sensitivity and selectivity enabling use in commercial applications unattainable by conventional ion mobility separation devices. The company was founded in 2015 and is headquartered in , Chadds Ford, PA. | Director/Board Member | 26/07/2022 |
| Aspen Global Leadership Network | Corporate Officer/Principal | - |
Formazione di Jenn Buechel
| Stanford University | Graduate Degree |
| Queen's University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
MOBILion Systems, Inc.
MOBILion Systems, Inc. Packaged SoftwareTechnology Services MOBILion Systems, Inc. offers paradigm-shifting platform technology. It will Develop a cost effective analytical system with a small footprint, high throughput, ultra-high sensitivity and selectivity enabling use in commercial applications unattainable by conventional ion mobility separation devices. The company was founded in 2015 and is headquartered in , Chadds Ford, PA. | Technology Services |
| Aspen Global Leadership Network | |
Delfi Diagnostics, Inc.
Delfi Diagnostics, Inc. Medical/Nursing ServicesHealth Services Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD. | Health Services |
- Borsa valori
- Insiders
- Jenn Buechel
